Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Investigating Near-Threshold Perception During Ultrasonic Deep Brain Stimulation

9 octobre 2026 mis à jour par: Zirui Huang, University of Michigan

This research is studying changes in awareness and metabolism in the brain that may take place in various brain regions stimulated with ultrasound (low-intensity focused ultrasound pulsation or LIFUP) while undergoing magnetic resonance imaging (MRI)-based brain measurements.

Aperçu de l'étude

Description détaillée

This study examines the effects of low-intensity focused ultrasound pulsation (LIFUP) on conscious perception and brain physiology in healthy adults using functional Magnetic resonance imaging (MRI), magnetic resonance spectroscopy, or multimodal glymphatic MRI. Participants are assigned by the study team to one of three arms, each involving up to five visits targeting different prespecified brain regions. Participants perform a visual perception task during imaging, with measurements obtained before, during, and after LIFUP. After completing their initially assigned arm, participants may re-enroll in another arm or for a repeat visit following re-screening and new informed consent.

Randomization applies to the order of procedures within each arm, not to assignment of participants among the three arms. The order in which the five brain regions are targeted will be randomized across participants in all three experimental arms

Type d'étude

Interventionnel

Inscription (Estimé)

90

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48109
        • University of Michigan
        • Contact:
        • Chercheur principal:
          • Zirui Huang
        • Chercheur principal:
          • Anthony Hudetz

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 40 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Participants must be right-handed, English-speaking, and capable of providing written informed consent.
  • Participants must have normal or corrected-to-normal vision while wearing contact lenses,
  • Participants must have a body mass index of less than 30
  • Participants must not be taking medications for any neurological, psychological, or psychiatric condition.

Exclusion Criteria:

  • Participants will be excluded if they have any contraindication to MRI scanning, including possible pregnancy, current breastfeeding BMI greater than 30, metallic substances or implants in the body, claustrophobia, anxiety that would prevent MRI scanning, Participants with tattoos in the head or neck region will also be excluded, while tattoos in other locations will be evaluated by the investigators to determine whether they pose a safety concern.
  • cardiopulmonary disease, or an intracranial structural abnormality identified on T1-weighted MRI.
  • Women of childbearing potential will be required to complete a study-funded pregnancy test before participation and must have a negative result.
  • vision that is not 20/20 or corrected to 20/20 with contact lenses, a history of significant head injury involving loss of consciousness
  • a learning disability or other developmental disorder
  • any sensory or motor impairment, activity, condition, or circumstance that, in the judgment of the study coordinator or Principal Investigators, would prevent satisfactory completion of the study protocol.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: LIFUP-fMRI

Participants assigned to the fMRI arm will complete five visits, with a different brain region targeted at each visit. Each visit will include seven consecutive 10-minute scanning periods: one pre-LIFUP baseline fMRI scan, five fMRI scans conducted during LIFUP using five predefined combinations of duty cycle and pulse repetition frequency, and one post-LIFUP baseline fMRI scan. The five stimulation parameter combinations will be labeled Combination 1 through Combination 5. The order of the five parameter combinations will be randomized within each visit. The total planned scanning time for these seven periods is approximately 70 minutes, excluding structural imaging, participant positioning, transducer placement, safety checks, and other required study procedures.

LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents.

Whole-brain functional images will be acquired using a multiband gradient-echo echo-planar imaging sequence with the following parameters: 60 slices, repetition time (TR) = 800 ms, echo time (TE) = 30 ms, flip angle = 52°, multiband acceleration factor = 6, slice thickness = 2.4 mm, in-plane resolution = 2.4 × 2.4 mm, FOV = 216 × 216 mm, and image matrix = 90 × 90. MRI acquisition and associated study procedures will be completed within a scanning visit lasting no more than approximately 2 hours.

Expérimental: LIFUP-magnetic resonance spectroscopy (MRS)

Participants assigned to the MRS arm will also complete five visits, with a different brain region targeted at each visit. Each visit will include a pre-LIFUP baseline MRS acquisition, an excitatory LIFUP condition, a post-excitatory non-LIFUP MRS acquisition, an inhibitory LIFUP condition, and a post-inhibitory non-LIFUP MRS acquisition. Each MRS acquisition period will last approximately 13 minutes and will include approximately 5 minutes of glutamate plus glutamine measurement and 8 minutes of gamma-aminobutyric acid (GABA) measurement. The order of the excitatory and inhibitory LIFUP conditions will be randomized across participants.

LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents.

Single-voxel proton magnetic resonance spectroscopy will be performed. A nominal 15 × 15 × 10 mm spectroscopy voxel will be positioned at the prespecified brain target using the participant's anatomical MRI. Glutamate plus glutamine (Glx) will be measured using a short-echo-time spectroscopy sequence with an acquisition time of approximately 5 minutes. GABA will be measured using an edited spectroscopy sequence with an acquisition time of approximately 8 minutes. An unsuppressed water-reference scan will also be acquired for signal correction and metabolite quantification. Voxel placement, shimming, and other sequence parameters may be adjusted slightly based on target anatomy, scanner requirements, and data quality while maintaining the planned procedures and approximate acquisition times.

Expérimental: LIFUP-Glymphatic MRI

Participants assigned to the glymphatic MRI arm will complete up to five visits, with a different prespecified brain region targeted at each visit. Tissue-to-fluid water exchange, velocity spectrum imaging, and cerebral perfusion using arterial spin labeling will be assessed before, during, and after LIFUP. The planned imaging periods total approximately 1.5 hours per visit, excluding participant positioning, structural imaging, transducer placement, safety checks, and other required study procedures.

LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents.

The study team will collect three separate measurements related to glymphatic function. (i) Multi-delay pseudo-continuous arterial spin labeling (PCASL) MRI with a 3D stack of spirals (SOS) gradient and spin echo (GRASE) read-out. Labeling durations from 500 to 2000 ms, TR = 6 sec., background suppression. FOV = 24 cm with 3x3x5 mm resolution. (ii) Tissue-to-fluid Water exchange rate using T2 selective saturation labeling pulses using the same resolution parameters. (iii) Velocity Spectrum Imaging using velocity selective preparation pulses followed by spherical spiral projection imaging (FOV = 24 cm, velocity bandwidth = [-1, 1] cm/s, isotropic spatial resolution = 3.5 mm).

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Blood Oxygen Level Dependent (BOLD) response to visual stimuli
Délai: Approximately 70 minutes

Changes in task-evoked blood oxygen level-dependent responses to visual stimuli will be measured using functional MRI before, during, and after LIFUP across the five stimulation parameter conditions.

Approximately 70 minutes

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Perceptual criterion (c) derived from the Signal Detection Theory (SDT)
Délai: Approximately 65-75 minutes

The perceptual response criterion, c, will be calculated from participants' recognition responses using Signal Detection Theory to quantify their tendency to report conscious recognition of a visual stimulus.

For each scanning session, the study team will calculate sensitivity (d') and criterion (c) using subjective reports of recognition as "yes" or "no".

Approximately 65-75 minutes
Perceptual sensitivity (d') derived from the Signal Detection Theory (SDT)
Délai: Approximately 75 minutes

Perceptual sensitivity, d', will be calculated from participants' visual discrimination responses using Signal Detection Theory to quantify their ability to distinguish intact object images from control stimuli.

For each scanning session, the study team will calculate sensitivity (d') and criterion (c) using subjective reports of recognition as "yes" or "no".

Approximately 75 minutes

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Zirui Huang, University of Michigan

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

30 novembre 2026

Achèvement primaire (Estimé)

1 mars 2032

Achèvement de l'étude (Estimé)

1 mars 2032

Dates d'inscription aux études

Première soumission

18 septembre 2026

Première soumission répondant aux critères de contrôle qualité

18 septembre 2026

Première publication (Réel)

25 septembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner